93M1 Fundamental Analysis - MPH HEALTH CARE AG KONV

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to 93M1. 93M1 was compared to 50 industry peers in the Pharmaceuticals industry. 93M1 scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 93M1 has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

93M1 had negative earnings in the past year.

In the past year 93M1 had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: 93M1 reported negative net income in multiple years.

In multiple years 93M1 reported negative operating cash flow during the last 5 years.

1.2 Ratios

With a Return On Assets value of -52.66%, 93M1 is not doing good in the industry: 82.00% of the companies in the same industry are doing better.

93M1 has a Return On Equity of -56.18%. This is in the lower half of the industry: 93M1 underperforms 78.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-52.66%
ROE	-56.18%
ROIC	N/A

ROA(3y)11.46%

ROA(5y)-0.71%

ROE(3y)12.15%

ROE(5y)-0.63%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

93M1's Profit Margin has improved in the last couple of years.

93M1 does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y32.91%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, 93M1 has about the same amount of shares outstanding.

93M1 has about the same amout of shares outstanding than it did 5 years ago.

The debt/assets ratio for 93M1 has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 4.67 indicates that 93M1 is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 4.67, 93M1 is in the better half of the industry, outperforming 72.00% of the companies in the same industry.

93M1 has a debt to FCF ratio of 5.58. This is a neutral value as 93M1 would need 5.58 years to pay back of all of its debts.

93M1 has a Debt to FCF ratio (5.58) which is comparable to the rest of the industry.

93M1 has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.

93M1 has a Debt to Equity ratio of 0.02. This is amongst the best in the industry. 93M1 outperforms 86.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	5.58
Altman-Z	4.67

ROIC/WACCN/A

WACC7.03%

2.3 Liquidity

93M1 has a Current Ratio of 0.40. This is a bad value and indicates that 93M1 is not financially healthy enough and could expect problems in meeting its short term obligations.

93M1 has a Current ratio of 0.40. This is amonst the worse of the industry: 93M1 underperforms 88.00% of its industry peers.

A Quick Ratio of 0.40 indicates that 93M1 may have some problems paying its short term obligations.

With a Quick ratio value of 0.40, 93M1 is not doing good in the industry: 88.00% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.4
Quick Ratio	0.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for 93M1 have decreased strongly by -196.45% in the last year.

Measured over the past years, 93M1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 23.67% on average per year.

The Revenue has grown by 104.72% in the past year. This is a very strong growth!

Measured over the past years, 93M1 shows a decrease in Revenue. The Revenue has been decreasing by -6.95% on average per year.

EPS 1Y (TTM)-196.45%

EPS 3YN/A

EPS 5Y23.67%

EPS Q2Q%-197.62%

Revenue 1Y (TTM)104.72%

Revenue growth 3Y-4.71%

Revenue growth 5Y-6.95%

Sales Q2Q%166.92%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 93M1. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

93M1's Price/Free Cash Flow ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	37.31
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.56%, 93M1 is a good candidate for dividend investing.

Compared to an average industry Dividend Yield of 3.10, 93M1 pays a better dividend. On top of this 93M1 pays more dividend than 96.00% of the companies listed in the same industry.

93M1's Dividend Yield is rather good when compared to the S&P500 average which is at 2.42.

		Industry Rank	Sector Rank
Dividend Yield	6.56%

5.2 History

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

DP0%

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MPH HEALTH CARE AG KONV

FRA:93M1 (9/26/2025, 7:00:00 PM)

18.3

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)09-16 2025-09-16

Earnings (Next)N/A N/A

Inst Owners0.96%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap78.32M

Analysts85.71

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	6.56%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1506.23
P/FCF	37.31
P/OCF	37.24
P/B	0.38
P/tB	0.38
EV/EBITDA	N/A

EPS(TTM)-26.91

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.49

FCFY2.68%

OCF(TTM)0.49

OCFY2.69%

SpS0.01

BVpS47.93

TBVpS47.93

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.66%
ROE	-56.18%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	4036.73%

ROA(3y)11.46%

ROA(5y)-0.71%

ROE(3y)12.15%

ROE(5y)-0.63%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y32.91%

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	5.58
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.4
Quick Ratio	0.4
Altman-Z	4.67

F-Score4

WACC7.03%

ROIC/WACCN/A

Cap/Depr(3y)20.66%

Cap/Depr(5y)19.86%

Cap/Sales(3y)15.7%

Cap/Sales(5y)12.57%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-196.45%

EPS 3YN/A

EPS 5Y23.67%

EPS Q2Q%-197.62%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)104.72%

Revenue growth 3Y-4.71%

Revenue growth 5Y-6.95%

Sales Q2Q%166.92%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-19.44%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-92.26%

FCF growth 3YN/A

FCF growth 5Y-24.11%

OCF growth 1Y-92.24%

OCF growth 3YN/A

OCF growth 5Y-24.28%

MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens